News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
615,259 Results
Type
Article (51091)
Company Profile (121)
Press Release (564037)
Multimedia
Podcasts (192)
Webinars (18)
Section
Business (163275)
Career Advice (2545)
Deals (29576)
Drug Delivery (128)
Drug Development (76613)
Employer Resources (146)
FDA (14939)
Job Trends (13290)
News (290868)
Policy (29516)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (2752)
Academic (1)
Accelerated approval (34)
Adcomms (32)
Allergies (141)
Alliances (42596)
ALS (175)
Alzheimer's disease (1722)
Antibody-drug conjugate (ADC) (320)
Approvals (15146)
Artificial intelligence (544)
Autoimmune disease (157)
Automation (39)
Bankruptcy (324)
Best Places to Work (10665)
BIOSECURE Act (20)
Biosimilars (175)
Biotechnology (75)
Bladder cancer (159)
Brain cancer (59)
Breast cancer (628)
Cancer (4759)
Cardiovascular disease (440)
Career advice (2157)
Career pathing (37)
CAR-T (270)
CDC (53)
Celiac Disease (2)
Cell therapy (738)
Cervical cancer (33)
Clinical research (65348)
Collaboration (1601)
Company closure (4)
Compensation (637)
Complete response letters (70)
COVID-19 (2797)
CRISPR (88)
C-suite (896)
Cystic fibrosis (134)
Data (6116)
Decentralized trials (2)
Denatured (69)
Depression (146)
Diabetes (496)
Diagnostics (6918)
Digital health (42)
Diversity (12)
Diversity, equity & inclusion (39)
Drug discovery (248)
Drug pricing (190)
Drug shortages (28)
Duchenne muscular dystrophy (239)
Earnings (61329)
Editorial (58)
Employer branding (20)
Employer resources (139)
Events (84778)
Executive appointments (1007)
FDA (17945)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (22)
Funding (1397)
Gene editing (190)
Generative AI (48)
Gene therapy (620)
GLP-1 (1018)
Government (4729)
Grass and pollen (8)
Guidances (380)
Healthcare (17072)
HIV (62)
Huntington's disease (47)
IgA nephropathy (84)
Immunology and inflammation (280)
Immuno-oncology (60)
Indications (109)
Infectious disease (3076)
Inflammatory bowel disease (187)
Inflation Reduction Act (16)
Influenza (119)
Intellectual property (244)
Interviews (539)
IPO (13336)
IRA (54)
Job creations (2949)
Job search strategy (1741)
JPM (65)
Kidney cancer (18)
Labor market (63)
Layoffs (538)
Leadership (40)
Legal (6364)
Liver cancer (92)
Longevity (14)
Lung cancer (666)
Lymphoma (370)
Machine learning (39)
Management (52)
Manufacturing (743)
MASH (179)
Medical device (11871)
Medtech (11919)
Mergers & acquisitions (17228)
Metabolic disorders (1318)
Multiple sclerosis (167)
NASH (23)
Neurodegenerative disease (341)
Neuropsychiatric disorders (100)
Neuroscience (3002)
Neurotech (1)
NextGen: Class of 2026 (6013)
Non-profit (4334)
Now hiring (57)
Obesity (630)
Opinion (286)
Ovarian cancer (164)
Pain (194)
Pancreatic cancer (227)
Parkinson's disease (277)
Partnered (31)
Patents (485)
Patient recruitment (484)
Peanut (53)
People (54415)
Pharmaceutical (27)
Pharmacy benefit managers (23)
Phase 1 (20168)
Phase 2 (28635)
Phase 3 (21775)
Pipeline (5257)
Policy (297)
Postmarket research (2535)
Preclinical (8545)
Press Release (60)
Prostate cancer (233)
Psychedelics (60)
Radiopharmaceuticals (258)
Rare diseases (879)
Real estate (4939)
Recruiting (63)
Regulatory (22831)
Reports (32)
Research institute (2420)
Resumes & cover letters (373)
Rett syndrome (27)
RNA editing (19)
RSV (76)
Schizophrenia (154)
Series A (235)
Series B (180)
Service/supplier (8)
Sickle cell disease (99)
Special edition (21)
Spinal muscular atrophy (161)
Sponsored (40)
Startups (3128)
State (2)
Stomach cancer (19)
Supply chain (97)
Tariffs (79)
The Weekly (121)
Vaccines (1027)
Venture capital (90)
Weight loss (421)
Women's health (92)
Worklife (19)
Date
Today (77)
Last 7 days (457)
Last 30 days (2041)
Last 365 days (27298)
2026 (3465)
2025 (27648)
2024 (31957)
2023 (35882)
2022 (46576)
2021 (50287)
2020 (49324)
2019 (42457)
2018 (32168)
2017 (29201)
2016 (28254)
2015 (32757)
2014 (24885)
2013 (20851)
2012 (22213)
2011 (23155)
2010 (20996)
Location
Africa (830)
Alabama (79)
Alaska (4)
Arizona (248)
Arkansas (12)
Asia (37491)
Australia (7605)
California (9727)
Canada (3080)
China (1062)
Colorado (423)
Connecticut (424)
Delaware (320)
Europe (85164)
Florida (1563)
Georgia (331)
Hawaii (1)
Idaho (57)
Illinois (785)
India (61)
Indiana (461)
Iowa (18)
Japan (411)
Kansas (119)
Kentucky (34)
Louisiana (25)
Maine (60)
Maryland (1267)
Massachusetts (6787)
Michigan (292)
Minnesota (520)
Mississippi (5)
Missouri (125)
Montana (27)
Nebraska (25)
Nevada (119)
New Hampshire (75)
New Jersey (2771)
New Mexico (27)
New York (2654)
North Carolina (1302)
North Dakota (7)
Northern California (4657)
Ohio (310)
Oklahoma (15)
Oregon (36)
Pennsylvania (2008)
Puerto Rico (24)
Rhode Island (40)
South America (1120)
South Carolina (62)
South Dakota (1)
Southern California (3900)
Tennessee (150)
Texas (1626)
United States (35232)
Utah (322)
Vermont (1)
Virginia (243)
Washington D.C. (68)
Washington State (828)
West Virginia (4)
Wisconsin (108)
Wyoming (2)
615,259 Results for "heartsciences formerly known as heart test labs".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
December 16, 2025
·
5 min read
Press Releases
University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
February 5, 2026
·
4 min read
Press Releases
HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results
July 25, 2025
·
6 min read
Business
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
Heart Test Laboratories, Inc.d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.
March 14, 2024
·
8 min read
Press Releases
Mira Named CES Innovation Awards Honoree for At-Home Lab-Quality Hormone Testing
January 6, 2026
·
2 min read
Press Releases
HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board
May 7, 2025
·
8 min read
Lone Star Bio
HeartSciences to Present at the LD Micro Invitational XIV Conference
Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York.
April 2, 2024
·
3 min read
Lone Star Bio
HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology
Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”) today announced that the Canadian Intellectual Property Office Application No. 3,000,369 has been granted by the Canadian Intellectual Property Office.
March 6, 2024
·
4 min read
Press Releases
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
June 4, 2025
·
5 min read
Business
HeartSciences Reports Second Quarter Fiscal 2024 Financial Results
Heart Test Laboratories, Inc.d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) today reported financial results for the second quarter fiscal 2024 ended October 31, 2023 and provided a business update.
December 14, 2023
·
7 min read
1 of 61,526
Next
